Table 2. TUR plus one immediate instillation followed by short-term versus long-term instillations during 12 mo.
Study | Year | Drug | % single tumors | Recurrence/total no. of patients | p | |
---|---|---|---|---|---|---|
Short-term instillations | Long-term instillations (12 mo) | |||||
Bouffioux [13] | 1995 | MMC 30 mg/50 ml | 62% | 70/160 (43.8%) | 67/150 (44.7%) | 0.87 |
ADM 50 mg/50 ml | ||||||
Okamura [14] | 1998 | Epirubicin 40 mg/40 ml | 67% | NA/69 (22.8%) | NA/69 (24.9%) | 0.62* |
2 yr | 2 yr | |||||
Koga [15] | 2004 | Epirubicin 30 mg/30 ml | 61% | 23/73 (31.5%) | 10/77 (13.0%) | 0.005* |
0.006 |
Treatment schedules: reference 13: 9 instillations during 6 mo vs. 15 instillations during 12 mo; reference 14: 6 instillations during 1 mo vs. 17 instillations during 12 mo; reference 15: 9 instillations during 3 mo vs. 19 instillations during 12 mo. TUR = transurethral resection; MMC = mitomycin C; ADM = Adriamycin; NA = not available.
Log-rank test.